NCI-N87 Transfection Reagent (Gastric Carcinoma, CRL5822)

Altogen Biosystems is a quality producer and research corporation for genetic research. Custom biological products and supplementary experiments include siRNA screening, optimization of preclinical research, quick cell line generation, RNAi testing and more. Dedicated to benefiting researchers with useful and specialized services, Altogen Biosystems aims to further modern pharmaceutical discoveries. Visit the website for a NCI-N87 xenograft model .

Derived from the metastatic tumor of a gastric cancer found in the liver of a human patient, NCI-N87 cells are known for their distinct expression of several factors; testing positive for ERBB2, myc, and other oncogenes, NCI-N87 cells are useful tools for research into lung cancer expression pathways. Cost-efficient therapy testing involving the cells can use pre-optimized transfection reagents to ensure realistic results that can translate to in vivo trials in human patients. Currently, there is a necessity for cheap drugs against lung cancer, which is one of the most prevalent cancers in non-developed countries. With more research and gene therapy development, accessible solutions can be found, with broader implications for the treatment of other variations of lung cancer.

The NCI-N87 epithelial cell line was originally established from the stomach tissue of a male patient with gastric carcinoma. They are extracted from the metastatic site located in the liver.  The NCI-N87 cells test positive for myc and ERRBB2 oncogenes,  express carcinoembryonic antigen (CEA), receptors for muscarinic cholinergic agents and TAG 72 surface glycoproteins.  Transfection Reagent for NCI-N87 Cells (Gastric Carcinoma Cells, CRL-5822)